72
Participants
Start Date
June 22, 2016
Primary Completion Date
April 6, 2020
Study Completion Date
April 6, 2020
Dapagliflozin
Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
Dapagliflozin placebo
matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
Research Site, Budapest
Research Site, Nyíregyháza
Research Site, The Bronx
Research Site, México, D.F.
Research Site, Buffalo
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Greenville
Research Site, Gainesville
Research Site, Miami
Research Site, Homestead
Research Site, Memphis
Research Site, Memphis
Research Site, Columbus
Research Site, Guadalajara
Research Site, Zapopan
Research Site, Monterrey
Research Site, Ẕerifin
Research Site, Lampasas
Research Site, McAllen
Research Site, Culiacán
Research Site, Beersheba
Research Site, Haifa
Research Site, Jerusalem
Research Site, Mérida
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Timișoara
Research Site, Rostov-on-Don
Research Site, Pyatigorsk
Research Site, Saratov
Research Site, Oradea
Research Site, Izhevsk
Research Site, Samara
Research Site, Novosibirsk
Research Site, Tomsk
Research Site, Krasnoyarsk
Research Site, Ramat Gan
Research Site, New Haven
Research Site, Boston
Research Site, Kent
Research Site, Leicester
Lead Sponsor
Collaborators (4)
Parexel
INDUSTRY
Q2 Solutions
INDUSTRY
PRA Health Sciences
INDUSTRY
Covance
INDUSTRY
AstraZeneca
INDUSTRY